Shares of Travere Therapeutics (NASDAQ: TVTX) are regaining some of the heavy losses its shareholders suffered in May. Enthusiasm for the biotech following another interim readout for sparsentan has driven the stock 15.5% higher as of 12:14 p.m. EDT on Monday.
Shares of Travere Therapeutics tanked in May after the FDA said it wouldn't accept the interim data the pivotal Duplex study with focal segmental glomerulosclerosis (FSGS) patients produced in February. The company and its investors had hoped proteinuria data at 36 weeks from the Duplex trial would be sufficient evidence of efficacy to support an application for accelerated approval.
Image source: Getty Images.
For further details see:
Here's Why Travere Therapeutics Stock Is Climbing Today